GLP-1 Biosimilars: How They Affect the Market and Access in 2026

GLP-1 based medications reshaped the treatment landscape for obesity and type 2 diabetes over the past few years. Semaglutide, tirzepatide, liraglutide. Names that once lived only in medical journals now dominate headlines and casual conversations about health. The problem is that the price remains prohibitive for most people. This is where biosimilars enter the picture.

A biosimilar is a version of an already approved biologic medication, with a molecular base that is similar but not identical to the original. Unlike common generic drugs, which are exact copies of small molecules, biologics are large and complex proteins. Copying a molecule of that size with absolute precision is impossible. What developers aim for is equivalence in efficacy and safety within strict regulatory margins.

Why biosimilars matter right now

The GLP-1 agonist market moved over 40 billion dollars globally in 2024. Demand outstrips supply in many regions. Manufacturers like Novo Nordisk and Eli Lilly dominate the segment with patents that are beginning to expire. When a biologic patent expires, competing companies can develop and commercialize biosimilar versions.

This pattern already played out with other biologic drug classes, such as anti-TNF agents used in autoimmune diseases. The result was significant price reduction, sometimes exceeding 50% of the original biologic's cost, and much greater patient access.

For GLP-1 drugs, patent expirations are starting to open that possibility in 2026. Several companies are already working on biosimilar versions of semaglutide and liraglutide. The FDA and the European Medicines Agency are receiving approval dossiers with increasing frequency.

What changes for patients

If biosimilars get approved and reach the market at lower prices, more people can access these treatments. The logic is straightforward. Lower medication costs mean more insurance plans agree to cover them, more public health systems can include them in treatment guidelines, and more pharmacies keep them in stock.

In practice, the transition is not instant. Biosimilars must go through comparability studies that demonstrate they are sufficiently similar to the reference product. This process takes years and consumes enormous resources. Companies need to show the biosimilar behaves clinically equivalently in pharmacokinetics, pharmacodynamics, efficacy, and safety.

Some physicians express concern about interchangeability, meaning whether a patient can switch freely between the reference biologic and the biosimilar without loss of efficacy. Regulators allow such switching when data supports it, but building that trust in clinical practice takes time.

The regulatory and competitive landscape

Europe is further ahead in GLP-1 biosimilar adoption than the United States in 2026. Public health systems like the NHS in the United Kingdom and several Nordic countries already include biosimilars of other biologics in their supply chains. The regulatory infrastructure is ready to absorb new approvals.

In the United States, the situation moves more slowly. The FDA has clear pathways for biosimilars, but the American market relies heavily on private insurers, and each one decides whether to cover a new biosimilar. Adoption tends to be more gradual, especially for high-cost medications like GLP-1 agents.

Biosimilar manufacturers from countries like India, South Korea, and China are watching the market closely. Companies like Biocon and Celltrion already produce biosimilars of other biologic agents and have the capacity to enter the GLP-1 space once patents allow.

Impact on insurers and public health systems

Insurers are pressured from all sides. Demand for GLP-1 medications for obesity is enormous, but the costs are staggering. When biosimilars arrive at lower price points, health plan managers can expand coverage with less financial impact.

Public health systems face the same dilemma. In Brazil, the SUS includes some biologic medications, but incorporating new drugs is a slow process through health technology assessment committees. If GLP-1 biosimilars arrive at competitive prices, the chance of incorporation increases considerably.

The Ozempro team recognizes that access is a real barrier for many people. Tools that help users understand their own usage patterns and available options make a difference when discussing treatment paths with a healthcare professional.

The platform also lets users log meals, mood, and energy levels throughout the day, building a personal record that makes conversations with doctors and nutritionists more productive when considering GLP-1 options.

What to expect in the coming years

The trend points toward price decreases as more biosimilars enter the market. Historically, biologic drug classes with the most biosimilar competition see reductions of 30% to 70% relative to the reference product price after a few years of competition.

For patients, this could mean that in three to five years, the monthly cost of a GLP-1 agonist is meaningfully lower than today. For physicians, it means having more prescribing options that fit both the clinical situation and the patient's budget.

Adverse event monitoring remains essential during this transition. Biosimilars are tracked by the same pharmacovigilance systems that monitor reference medications. Any unexpected safety signal needs to be reported and investigated.

The GLP-1 market is shifting rapidly. For people using or considering these medications, staying informed about these changes helps make better decisions and have more productive conversations with their doctor about what makes the most sense for their situation.

---

Words: 960

References

• EMA — Mounjaro (tirzepatida), EPAR
• Jastreboff et al., SURMOUNT-1 — NEJM (2022)
• OMS — Obesity and overweight, fact sheet